Oddo Bhf set a €93.00 ($114.81) target price on MorphoSys (ETR:MOR) in a research note published on Wednesday, March 14th. The firm currently has a buy rating on the stock.
A number of other equities research analysts also recently issued reports on MOR. Goldman Sachs set a €80.00 ($98.77) price objective on shares of MorphoSys and gave the stock a neutral rating in a research note on Monday, November 27th. Independent Research set a €93.00 ($114.81) target price on shares of MorphoSys and gave the stock a buy rating in a report on Friday, December 1st. Berenberg Bank set a €85.00 ($104.94) target price on shares of MorphoSys and gave the stock a buy rating in a report on Thursday, December 7th. JPMorgan Chase set a €86.00 ($106.17) target price on shares of MorphoSys and gave the stock a buy rating in a report on Tuesday, December 12th. Finally, HSBC set a €64.00 ($79.01) target price on shares of MorphoSys and gave the stock a sell rating in a report on Friday, January 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of €84.02 ($103.73).
MorphoSys stock traded down €0.55 ($0.68) during trading hours on Wednesday, reaching €78.85 ($97.35). 87,105 shares of the stock were exchanged, compared to its average volume of 153,687. MorphoSys has a twelve month low of €49.63 ($61.27) and a twelve month high of €88.10 ($108.77).
TRADEMARK VIOLATION WARNING: “MorphoSys (ETR:MOR) Given a €93.00 Price Target by Oddo Bhf Analysts” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/morphosys-mor-given-a-93-00-price-target-by-oddo-bhf-analysts.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.